A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

← catalyst calendar

NCT05057494 · readout in 330 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

607actual

Sites

Countries

Australia, Czechia, France +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-09-12

actual

When the study began enrolling

Primary completion

2027-07-15

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-04-10

estimated

The whole study's end, after follow-up

First posted

2021-09-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions

Drug: Acalabrutinib
Drug: Venetoclax
Drug: Obinutuzumab

Primary outcome

what the primary-completion date above is the date OF

Progression-free Survival (PFS)

measured Until progressive disease (PD) [assessed Up to 6.6 Years].

Publications

PMID 36102212 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed